bictegravir emtricitabine tenofovir
Selected indexed studies
- Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial. (Lancet HIV, 2023) [PMID:37567205]
- Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection. (Drugs, 2018) [PMID:30460547]
- Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial. (Lancet HIV, 2025) [PMID:40489982]
_Worker-drafted node — pending editorial review._
Connections
bictegravir emtricitabine tenofovir is a side effect of
Sources
- Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. (2017) pubmed
- Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial. (2023) pubmed
- Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection. (2018) pubmed
- Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial. (2025) pubmed
- Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial. (2023) pubmed
- Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. (2020) pubmed
- Bictegravir/emtricitabine/tenofovir alafenamide for HIV infection. (2019) pubmed
- Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials. (2023) pubmed
- Bictegravir/Emtricitabine/Tenofovir Alafenamide for HIV-1: What is the Hidden Potential of This Emerging Treatment? (2023) pubmed
- Pharmacokinetic evaluation of bictegravir + emtricitabine + tenofovir alafenamide in HIV treatment. (2024) pubmed